Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Oligodendroglioma × Tretinoin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Promyelocytic, Acute 3 Multiple Myeloma 2 Sarcoma 1 Oligometastatic Disease 1 Oligodendroglioma 1 Neoplasm Metastasis 1 Leiomyosarcoma 1 HER2 Negative Breast Cancer 1 Glioma 1 Astrocytoma 1

Interventions

Temozolomide 5 Radiotherapy 5 Bevacizumab 2 tislelizumab 1 olutasidenib 1 abexinostat 1 Vincristine 1 Tretinoin 1 Radiation 1 Procarbazine 1 ONC206 1 Lomustine 1 Cetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05345002 2026-02-20

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Astrocytoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡